

# 1 Brief Research Report

## 2 **Characteristics and outcomes of cases of children and adolescents with** 3 **pediatric inflammatory multisystem syndrome in a tertiary care center** 4 **in Mexico City**

5 **Ricardo Gil Guevara**<sup>1†</sup>, **María de Lourdes Marroquín Yáñez**<sup>2 †</sup>, **Rodolfo Norberto Jiménez-**  
6 **Juárez**<sup>3,4</sup>, **Víctor Olivar Lopez**<sup>1</sup>, **Adrián Chávez Lopez**<sup>2</sup>, **Juan José Luis Sierra Monge**<sup>5</sup>,  
7 **Lourdes Maria del Carmen Jamaica Balderas**<sup>6</sup>, **Silvia Alexandra Martínez Herrera**<sup>1</sup>, **Clemen**  
8 **Domínguez-Barrera**<sup>3</sup>, **Julio Erdmenger Orellana**<sup>7</sup>, **Horacio Márquez González**<sup>8</sup>, **Miguel**  
9 **Klünder-Klünder**<sup>9</sup>, **Jaime Nieto Zermeño**<sup>10</sup>, **Mónica Villa Guillen**<sup>10</sup>, **Nadia González García**<sup>11</sup> \*,  
10 **Maria F Castilla-Peon**<sup>12</sup> \*

11 †These authors have contributed equally to this work and share first authorship

12 \*These authors have contributed equally to this work and are both corresponding authors

13  
14 <sup>1</sup> Emergency Medicine Department, Hospital Infantil de Mexico Federico Gomez Instituto Nacional de Salud, Mexico  
15 City, Mexico

16 <sup>2</sup> Pediatric Intensive Care Unit, Hospital Infantil de Mexico Instituto Nacional de Salud, Mexico City, Mexico <sup>3</sup> Infectious  
17 Diseases Department, Hospital Infantil de Mexico Federico Gomez Instituto Nacional de Salud, Mexico City, Mexico.

18 <sup>3</sup> Department of Infectious Diseases, Hospital Infantil de Mexico Federico Gomez Instituto Nacional de Salud, Mexico  
19 City, Mexico.

20 <sup>4</sup> Department of Pediatrics, Infectious Diseases Hospital, UMAR National Medical Center “La Raza”, Instituto Mexicano  
21 del Seguro Social, Ciudad de Mexico, Mexico

22 <sup>5</sup> Ambulatory Pediatrics, Hospital Infantil de Mexico Federico Gomez Instituto Nacional de Salud Instituto Nacional de  
23 Salud, Mexico City, Mexico.

24 <sup>6</sup> Respiratory Medicine Department, Hospital Infantil de Mexico Federico Gomez Instituto Nacional de Salud, Mexico  
25 City, Mexico.

26 <sup>7</sup> Cardiology Department, Hospital Infantil de Mexico Federico Gomez Instituto Nacional de Salud, Mexico City, Mexico

27 <sup>8</sup> Department of Clinical Research, Hospital Infantil de Mexico Federico Gomez Instituto Nacional de Salud, Mexico  
28 City, Mexico

29 <sup>9</sup> Research Division, Hospital Infantil de Mexico Federico Gomez Instituto Nacional de Salud, Mexico City, Mexico

30 <sup>10</sup> Hospital Infantil de Mexico Federico Gomez Instituto Nacional de Salud, Mexico City, Mexico

31 <sup>11</sup> Neurosciences Research Laboratory, Hospital Infantil de Mexico Federico Gomez Instituto Nacional de Salud, Mexico  
32 City, Mexico

33 <sup>12</sup> Research Division, Hospital Infantil de Mexico Federico Gomez Instituto Nacional de Salud, Mexico City, Mexico

### 34 \* Correspondence:

35 Maria F. Castilla-Peon [fernandacastillapeon@gmail.com](mailto:fernandacastillapeon@gmail.com)

36 Nadia Gonzalez-García [nadia.him@gmail.com](mailto:nadia.him@gmail.com)

37  
38  
39 **Words (Without abstract, references and tables) : 3413**

40 **American English**

41 **Tables: 3**

42 **Figures:1**

43

44

## 45 **Characteristics and outcomes of cases of children and adolescents with** 46 **pediatric inflammatory multisystem syndrome in a tertiary care center** 47 **in Mexico City**

### 48 **Abstract**

49 **Background:** pediatric inflammatory multisystem syndrome (PIMS) is a complication of severe  
50 acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children that resembles  
51 Kawasaki syndrome and places them at high risk of cardiorespiratory instability and/or cardiac  
52 damage. This study aims to describe the clinical presentation and outcomes of patients with PIMS in  
53 Mexico City.

54 **Methods:** This was an observational study of children hospitalized for PIMS based on the Centers  
55 for Disease Control and Prevention case definition criteria, in a single tertiary care pediatric center in  
56 Mexico City between May 1, 2020, and September 30, 2021. Demographic characteristics,  
57 epidemiological data, medical history, laboratory tests, cardiology evaluations, treatment, and clinical  
58 outcomes were analyzed.

59 **Results:** Seventy-five cases fulfilled the case definition criteria for PIMS (median age: 10.9 years,  
60 Interquartile range [IQR]: 5.6–15.6). Fifteen (20%) patients had a severe underlying disease, 48  
61 (64%) were admitted to the intensive care unit, 33 (44%) required invasive mechanical ventilation  
62 and 39 (52%) received vasopressor support. The patients were clustered through latent class analysis  
63 based on identified symptoms: Cluster 1 had rash or gastrointestinal symptoms (n = 60) and cluster 2  
64 were those with predominantly respiratory manifestations (n = 15). Two patients (2.7%) died, and  
65 both had severe underlying conditions. Five patients (6.7%), all from cluster 1, developed coronary  
66 aneurysms.

67 **Conclusion:** There were a high proportion of patients with severe respiratory involvement and  
68 positive RT-PCR SARS-CoV-2 and very few cases of coronary aneurysms in our study which  
69 suggests that a high proportion of the children had severe acute COVID-19. The clinical  
70 manifestations and outcomes are comparable to previously reported international studies.

### 71 **1 Introduction**

72 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection usually has a mild clinical  
73 presentation in children. However, in rare cases, children can be severely affected and have clinical  
74 manifestations, different from adults. In April 2020, some reports described a clinical syndrome  
75 similar to Kawasaki disease or toxic shock syndrome temporally associated with current or recent  
76 SARS-CoV-2 infection in the pediatric population (1). Since then, this syndrome has been  
77 recognized worldwide and named pediatric inflammatory multisystem syndrome (PIMS) or  
78 multisystem inflammatory syndrome in children (MIS-C) (2–6).

79 PIMS case definition varies slightly between different health agencies (7–9) and it is likely to change  
80 over time. The criteria include fever, inflammatory marker elevation, multisystem organ  
81 involvement, evidence of current or recent SARS-CoV-2 infection, and exclusion of alternative  
82 diagnoses. Besides the need for hospitalization for life support, an outcome of concern is myocardial  
83 and coronary artery involvement similar to those observed in Kawasaki disease (10–12).

84 PIMS incidence has been estimated to be approximately 3–5 per 10,000 individuals younger than 21  
85 years of age infected with SARS-CoV-2, and Black and Hispanic ethnicities have been associated  
86 with a higher incidence (13). Epidemiological description of PIMS has been difficult because of  
87 varying awareness of the condition in different clinical scenarios and because of the diversity of  
88 clinical manifestations. Besides, there is an overlap between the clinical manifestations of severe  
89 acute COVID-19 and PIMS (10). Hence, the current PIMS case definition is purposely broad and  
90 unspecific to obtain maximum and comprehensive information about this phenomenon. However,  
91 increasing evidence suggests the existence of different phenotypes of PIMS, the more clearly defined  
92 of them being a Kawasaki-like syndrome, a toxic shock-like syndrome, and a predominantly  
93 respiratory syndrome which might have different pathogenesis and clinical outcomes (14–16).

94 This study aims to describe the clinical characteristics and outcomes of PIMS cases admitted to a  
95 tertiary care pediatric center in Mexico City. **A secondary aim was to define potential clinical**  
96 **subgroups of children with PIMS.**

## 97 **2 Materials and Methods**

### 98 **2.1 Study design**

99 This was **an observational prospective** study of PIMS cases diagnosed in ‘Hospital Infantil de  
100 Mexico Federico Gómez’ (Federico Gómez Mexico Children’s Hospital), a tertiary care pediatric  
101 facility officially designated to treat patients with severe SARS-CoV-2 infection who are less than 18  
102 years old, and without public or private health insurance in Mexico City.

103 Probable PIMS cases were identified in the emergency room, transferred from other health care  
104 facilities directly to the intensive care unit, or identified by treating physicians in the general  
105 hospitalization ward for COVID-19 patients. Cases were evaluated to determine if they met the  
106 Centers for Disease Control and Prevention (CDC) PIMS case definition (7). This case definition  
107 included the presence of fever, the elevation of inflammatory markers, signs of involvement of at  
108 least two organ systems requiring hospitalization, and evidence of recent SARS-CoV-2 exposure or  
109 infection. Patients were excluded if they had another plausible explanation for the illness. When there  
110 was uncertainty about an alternative diagnosis, the complete case file was reviewed by an expert  
111 panel which included an infectious disease specialist and a critical care specialist, until a consensus  
112 was reached. Detailed inclusion criteria are specified in Chart 1.

### 113 **2.2 Data collection**

114 Clinical and laboratory data were extracted from the patients’ clinical file and included  
115 demographics, underlying medical conditions, clinical manifestations, laboratory values,  
116 management, and outcomes. For laboratory values with more than one measurement, the worst value  
117 measured within the first three days of hospitalization was obtained. Vital support management  
118 (respiratory support and vasopressor utilization), intravenous immune globulin, systemic steroids,  
119 and anticoagulant therapy were documented as the main therapeutic interventions. Outcomes of  
120 interest were intensive care unit (ICU) admission, length of ICU stay and hospitalization, need for  
121 invasive mechanical ventilation, vasopressor support, myocardial depression (left ventricular ejection  
122 fraction < 55%), coronary aneurysms (coronary artery diameter z-score  $\geq 2.5$ ), or dilatation (z-score  
123  $>2$ – $<2.5$ ) on the echocardiographic evaluation performed during hospitalization, and in-hospital  
124 mortality. Markers with more than 20% missing data were not analyzed.

125 For this study, severe respiratory involvement was defined as infiltrates on chest X-ray or computed  
126 tomography plus the need for oxygen administration with a non-rebreathable mask or a higher  
127 oxygen concentration device. The variable ‘gastrointestinal symptoms’ was defined as the presence  
128 of at least one of the following: abdominal pain, diarrhea, or emesis.

129 The study center has an important regular population of patients with severe underlying diseases.  
130 Hence, to have a picture more alike general population, we performed a sub-analysis with the  
131 exclusion of cases with severe underlying diseases (i.e., cancer and other forms of  
132 immunosuppression diseases, neuromuscular disability, chronic respiratory disease except for  
133 asthma, congenital cardiopathies, and chronic kidney failure).

### 134 2.3 Statistical analysis

135 Descriptive analysis was conducted using STATA v.14.0 (StataCorp, Tx). Categorical variables were  
136 reported as frequencies and continuous variables as medians and interquartile ranges (IQR). Analysis  
137 was performed on the whole sample and three subgroups. In the first subgroup, cases with severe  
138 underlying conditions were excluded. The other two subgroups were identified using latent class  
139 analysis (LCA). Two class LCA were conducted using the R software package ‘poLCA’ (17) with  
140 100 iterations to identify the clusters. The indicator variables used in LCA were the presence or  
141 absence of severe respiratory involvement, rash and gastrointestinal symptoms. The fit of each model  
142 was assessed using a Bayesian Information Criterion score.

143 The study was approved by the ethics review board of Federico Gómez Mexico Children’s Hospital  
144 (Reg: HIM2020-031), including the publication of de-identified data.

## 145 3 Results

146 Reports of one hundred and sixty-seven (167) probable cases of PIMS admitted to the hospital  
147 between May 1, 2020, and September 30, 2021, were sent by clinical departments. For reference,  
148 during this period, 8,193 real-time polymerase chain reaction (RT-PCR) tests for SARS-CoV-2 were  
149 performed in the study center, which yielded 837 positive results. **The temporal distribution of  
150 cases follows the pattern of the three epidemic peaks in Mexico City during the study period  
151 (Figure 1).**

152 From the 167 received reports, 42 were from the emergency department, 34 from the ICU, and 91  
153 from the infectious disease department. Duplicated reports were eliminated (n = 23) and 23 reports  
154 failed to meet inclusion criteria. **Severe conditions were not unusual among patients being  
155 attended at the study center. Besides, testing for SARS-CoV-2 is performed routinely before  
156 hospital admission. Hence, the scenario of SARS-CoV-2 infection in a severely ill patient was  
157 common in the received reports. Forty-six cases were excluded because either elevated  
158 inflammation markers or system failures had an obvious cause other than the exposure to  
159 SARS-CoV-2. Of these, in 13 cases an infectious process other than SARS-CoV-2 was  
160 identified, such as acute complicated appendicitis (n=5), positive blood cultures (n=3), neck  
161 abscess (n=2), aspergillosis (n=1), neutropenic colitis (n=1), and influenza coinfection (n=1). In  
162 6 cases, lymphopenia and/or thrombocytopenia were attributed to drugs, mainly antineoplastic  
163 chemotherapy. Five cases presented with a new onset malignancy, two had a reactivation of  
164 systemic lupus erythematosus, one had a macrophage activation syndrome associated with  
165 idiopathic juvenile arthritis and one case was diagnosed with Kawasaki syndrome (no evidence  
166 of SARS-CoV-2 exposure was found in this case). Other excluded cases which did not meet  
167 criteria for PIMS aside from the organic failure attributed to the comorbid condition, had**

168 **congenital cardiopathies (n=5), neurologic conditions (n=3), chronic renal disease (n=2),**  
169 **ketoacidosis (n=2), aplastic anemia, digoxin intoxication, post cardiorespiratory arrest status,**  
170 **histiocytosis, intestinal occlusion, and a vascular neoplasm which originated consumption**  
171 **coagulopathy. Of the 46 excluded cases, only the one diagnosed with Kawasaki syndrome**  
172 **received intravenous immune globulin (IVIG).**

173 **Among the 75 included cases there was only one case presenting with clinical manifestations of**  
174 **acute abdomen and was operated in the referring health care center. This case was transferred**  
175 **to the study center because of his poor evolution after surgery and we do not have information**  
176 **on the surgical findings. Other cases presenting with acute abdomen (n=5) were not included in**  
177 **the analysis because surgical findings explained the inflammatory clinical manifestations.**

178 The results for the 75 included cases are as follow: the median (interquartile range [IQR]) age was  
179 10.9 (5.6-15.6) years and more than half (52%) were females. A total of 45.3% of the participants  
180 had at least one underlying condition, including obesity (25%), cancer (9%), neuromuscular (8%),  
181 and respiratory (7%) diseases (Table 1).

182 In addition to fever, the most common clinical manifestations were cough (52%), conjunctivitis  
183 (50.6%), abdominal pain (51%), rash (48%), headache (45.3%), and diarrhea (44%). The median  
184 (IQR) duration of symptoms before admission was 7 (4–9) days. About 51% had lower respiratory  
185 symptoms, 85% had pulmonary infiltrates on radiograph or computed tomography, and 65.3%  
186 required oxygen administration with a non-rebreathable mask, high flow nasal cannula, or  
187 mechanical ventilation. Vasopressor support was used in 52% of the cases, and about 40% had a left  
188 ventricular ejection fraction <55% on echocardiography. Median values for markers of inflammation,  
189 coagulation, and system damage are summarized in Table 1.

190 Three subgroups were analyzed independently. In the first subgroup (n = 60), 15 cases with severe  
191 underlying disease were excluded. Clinical manifestations and outcomes did not differ significantly  
192 from those observed in the total sample (Tables 1 and 2).

193 The second (n = 60) and third (n = 15) subgroups were derived from LCA which identified two  
194 classes of patients: cluster 1 (n = 60) comprised of patients with rash and/or gastrointestinal  
195 symptoms, and cluster 2 (n = 15) comprised of those with predominantly cardiorespiratory  
196 involvement, without a rash or gastrointestinal symptoms. Despite the small number of cases in  
197 cluster 2, some differences were evident: cluster 2 cases were more prone to having a positive RT-  
198 PCR test (100% vs 76%, p = 0.04) and less likely to have a positive serology test (0% vs 54%, p <  
199 0.001). An underlying medical condition was also more frequent in cluster 2 (80% vs 36.7%, p =  
200 0.003), especially a severe one (47% vs 13%, p = 0.008) such as cancer, neuromuscular disability, or  
201 a chronic respiratory condition (Table 1). Cluster 1 patients tended towards higher levels of  
202 inflammation markers, though the difference was statistically significant for only the neutrophil  
203 count and D-Dimer concentration.

204 With regards to treatment, 45.3%, 64% and 63% of the cases received intravenous immune globulin,  
205 systemic steroids, and anticoagulation therapy respectively, which was more frequent in the cluster 1  
206 group (Table 2). For outcomes, two (2.7%) patients died and they both had severe underlying  
207 diseases; the first patient had a medulloblastoma and died two weeks after the antineoplastic  
208 chemotherapy dose while the second one had chronic kidney failure (20) and was on renal  
209 replacement therapy. One death occurred in each cluster group. About 44% of the cases needed



210 mechanical ventilation, 52% required vasopressor support while 40% had a depressed ventricular  
211 function. (Table 2)

212 All cases had an echocardiographic evaluation during hospitalization. Five cases (6.7%) had coronary  
213 aneurysms and notably, all these cases were in cluster 1. No patient had a coronary diameter with a z-  
214 score between 2.0 and 2.5. Myocardial involvement (left ventricular ejection fraction < 55%) was  
215 observed in 30 (40%) of the cases. ICU admission occurred in 64% of the cases with a median (IQR)  
216 length of ICU stay of 5 (3–8) days and a length of hospital stay of 7 (4–13). There was a tendency of  
217 cluster 2 patients to remain longer in ICU and the hospital. (Table 2).

218 **The third epidemic wave started at the beginning of June 2021 (18) and was attributed mainly**  
219 **to the Delta variant of SARS-CoV-2, this variant being identified in about 80% of sequenced**  
220 **samples at the peak of this wave in mid-July (19). Eleven of the analyzed PIMS cases occurred**  
221 **after June 1<sup>st</sup>, 2021. An exploratory analysis to compare outcomes between cases presenting**  
222 **before and after June 1<sup>st</sup> showed that eleven PIMS cases occurred in the later period (Figure 1).**  
223 **A lower frequency of UTI admission was observed in this later period (36.4 vs 68.8%, p =0.05),**  
224 **and no deaths.**

#### 225 4 Discussion

226 To our knowledge, the present study described the largest cohort of patients with PIMS in the  
227 Mexican population to date. Most clinical characteristics and outcomes were similar to those  
228 described in large international reports. The median age of our sample was higher than most of these  
229 previous reports. The prevalence of underlying medical conditions, including obesity, was similar to  
230 the reported data in the United States and Latin America (10,16,21–23), except for cancer which was  
231 relatively more frequent in our total sample, reflecting the characteristics of the population regularly  
232 attending the study site. Cardiac dysfunction, vasopressor requirements, rash, gastrointestinal  
233 symptoms, ICU admissions, and lengths of hospital and ICU stay were comparable to those reported  
234 elsewhere. The death rate of 2.7% (binomial 95% confidence interval: 0.3%–9.3%) was also  
235 consistent with previous reports (3,5,10,14,21,24).

236 Our population had a relatively high frequency of lower and serious respiratory involvement in  
237 comparison with most of the other studies. Besides, in our sample, serology was performed in only  
238 55% of the cases, so the evidence of SARS-CoV-2 infection in our population was mostly by RT-  
239 PCR (80% positivity rate). These findings point toward a higher proportion of acute severe SARS-  
240 CoV-2 infection vs a theoretical late-onset post-infectious syndrome compared to other case series  
241 where respiratory involvement and RT-PCR positive rate was lower (3,5,10,14,21). Current PIMS  
242 diagnostic criteria do not exclude acute severe COVID-19; this overlap between both clinical  
243 presentations has been previously discussed (10,16).

244 On the other hand, the frequency of coronary aneurysms in our study was relatively low (6.7%). The  
245 frequency of aneurysms varied, ranging from 6.7% to 23.3% in previous studies (14,21,22,24). This  
246 probably reflects the lack of specificity in the PIMS case definition criteria and the variability of the  
247 cut-point for some inflammatory markers used in different reports. Most case series are derived from  
248 active or passive surveillance, either retrospectively or prospectively. Many of them do not inform a  
249 cut-point for inflammatory markers concentration, or clinical symptoms and the upper limit of the  
250 normal reference range may have been used. This probably explains the high frequency of coronary  
251 aneurysms (23.3%) found by Flood et al., in the United Kingdom. Their study had a very high cut-  
252 point of 100mg/L for C-reactive protein and required ‘acute abdomen’ and very specific

253 dermatological findings, in addition to ‘abdominal pain’ or ‘rash’ as criteria for gastrointestinal or  
254 mucocutaneous involvement respectively (14). Stringency in diagnostic criteria automatically  
255 excludes a high proportion of potential cases, thus ensuring a more homogeneous and severely  
256 affected population.

257 **While clinical and epidemiological studies point toward the existence of at least two different**  
258 **clinical presentations of severe illness associated with SARS-CoV-2 infection (i.e., acute severe**  
259 **COVID-19 vs. PIMS) (10,15,16,25,26), a clear-cut distinction between the clinical and physio-**  
260 **pathological features of each one has remained elusive. On the one hand, severe COVID-19 is**  
261 **supposed to be the expression of an acute pulmonary infection with high viral loads; on the**  
262 **other hand, PIMS is conceived as a post-infectious syndrome with an exacerbated immune**  
263 **activation (9,27,28). Regarding physiopathology, some studies have identified different**  
264 **immunological profiles between pediatric acute COVID-19 and PIMS (29,30); however, these**  
265 **studies fail to include groups of patients with severe-acute COVID-19 and of SARS-CoV-2**  
266 **infected patients with severe coexisting comorbidities. Our study does include these two last**  
267 **groups of cases, which led to a more pronounced overlap and effacement between groups.**

268 Although ours was a small sample to make any inference, it supports the increasing awareness about  
269 the existence of different clinical phenotypes within positive PIMS criteria. Patients included in our  
270 cluster 1 were characterized by the presence of rash or gastrointestinal symptoms, with higher levels  
271 of some inflammatory markers. Custer 2 cases had a clinical presentation with predominant  
272 respiratory manifestations as described in severe acute COVID-19.

273 **Some researchers have tried to define subgroups within patients who fulfill PIMS criteria. We**  
274 **tested several LCA-derived models using factors described in previous attempts to classify**  
275 **cases. (14–16), and finally selected the current model which includes three factors (i.e., rash,**  
276 **gastrointestinal involvement, and severe respiratory involvement) as the one with the best**  
277 **balance between fit (i.e., Bayesian Information Criterion score) and parsimony. Godfred-Cato et**  
278 **al. (15), and later Geva et al. (16), identified three classes of patients: 1) a seriously ill group with**  
279 **significant cardiovascular involvement, multiple organ dysfunction, a pronounced elevation of**  
280 **inflammatory markers with a tendency of positive serology for SARS-CoV-2, 2) a group with**  
281 **predominantly respiratory involvement and high RT-PCR positivity rate that resembles our cluster 2**  
282 **group and 3) a group with predominantly Kawasaki-like mucocutaneous findings. Meanwhile, Flood**  
283 **et al. also identified three PIMS phenotypes using cluster analysis: 1) PIMS with Kawasaki disease-**  
284 **like presentation, 2) PIMS with findings similar to Kawasaki disease and shock and 3) PIMS without**  
285 **any of these features (14). Accordingly, consensus-derived clinical recommendations have been**  
286 **generated (31). Of note, Flood specified very high cutting points of laboratory and clinical signs**  
287 **to qualify as a PIMS, thus getting a more homogeneous sample and with higher levels of**  
288 **inflammation than we did. This circumstance and a bigger sample size let them classify cases in**  
289 **more categories and with subtler differences than we did.**

290 In all three cluster analyses, coronary artery aneurysms were more frequent in groups with Kawasaki-  
291 like features and higher levels of inflammatory markers, which corresponds to cluster 1 in our cluster  
292 analysis. Notably, none of the five aneurysm cases in our sample had serious underlying diseases and  
293 all of them belonged to cluster 1 (Mucocutaneous/gastrointestinal predominant symptoms).

294 The role of inflammation in the spectrum of severe illness associated with SARS-CoV-2 infection  
295 should be deeply studied, including its role in myocardial dysfunction since it is a frequent  
296 complication both in adults with COVID-19 and children with PIMS (32). **The resemblance of**  
297 **PIMS with Kawasaki disease and the notion of a dysregulated immune activation has led to the**

298 **utilization of a similar therapeutic approach with intravenous immune globulin and**  
299 **glucocorticoids (33), as well as the presumption of the possible effectiveness of immune**  
300 **modulators such as tumor necrosis factor, interleukin-1, and interleukin-6 inhibitors.**

301 A limitation of this study, as in others, is the method for identification of included cases for analysis,  
302 which depended on spontaneous reports by treating clinicians. In the future, a prospective  
303 multicentric cohort study with clear-cut criteria for subclassification of every patient fulfilling the  
304 PIMS broad clinical criteria after SARS-CoV-2 infection would provide more information on the  
305 outcomes and possible associated factors.

306 **Other limitations of the study are those inherent to the retrospective design which bias results**  
307 **towards the identification of more severe cases and to the lack of some data in the clinical files.**  
308 **It would have been desirable to have had the SARS-CoV-2 serology for every case as well as**  
309 **myocardial damage biomarkers. On the other hand, one of the strengths of the study is the**  
310 **availability of an echocardiographic evaluation of almost all patients, since heart involvement is**  
311 **one of the most feared complications associated with SARS-CoV-2 infection in children.**

## 312 **5 Conclusions**

313 The epidemiology of PIMS cases observed in our center is comparable to those reported elsewhere,  
314 although our study included a high proportion of patients with an acute respiratory phenotype.  
315 Coronary aneurysms were uncommon and usually present in previously healthy patients with rash or  
316 gastrointestinal symptoms.

317 It might be important to differentiate the clinical subtypes diagnosed as PIMS under the umbrella of  
318 CDC and WHO case definition criteria since probably not all of them benefit from the same  
319 therapeutic interventions.

320 The death rate paralleled previous reports and occurred in patients with severe underlying diseases.

321 This study agrees with other researchers that in the context of case definition criteria for COVID-19,  
322 at least two groups of patients can be identified according to their clinical presentation. Standardized  
323 criteria for subclassification of PIMS(28) cases need to be developed, since different phenotypes  
324 might have different pathophysiology, different outcomes, and possibly require different  
325 management. Clinical trials are needed to evaluate therapeutic interventions for different PIMS  
326 phenotypes.

## 327 **6 Conflict of Interest**

328 The authors declare that the research was conducted in the absence of any commercial or financial  
329 relationships that could be construed as a potential conflict of interest.

## 330 **7 Author Contributions**

331 All authors contributed to the study plan and design. RGG, MLMY, RNJJ, VBOL, CDB collected the  
332 data. HMG coordinated the research team. MFCP and NGG performed the data analysis and wrote  
333 the first draft of the manuscript. All authors reviewed and approved the final manuscript.

## 334 **8 Funding**



335 This study was funded by Hospital Infantil de Mexico Federico Gómez.

## 336 **9 Data Availability Statement**

337 The datasets generated for this study can be requested to corresponding authors.

## 338 **10. Captions**

339 **Figure 1.** Temporal distribution of PIMS cases by cluster from May 1<sup>st</sup>, 2020 (Week 19, 2020) to  
340 September 30, 2021 (Week 40, 2021).

341

## 342 **11. References**

343

- 344 1. Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory  
345 shock in children during COVID-19 pandemic. *Lancet*. 2020;395(10237):1607–8.
- 346 2. Cheung EW, Zachariah P, Gorelik M, Boneparth A, Kernie SG, Orange JS, et al. Multisystem  
347 Inflammatory Syndrome Related to COVID-19 in Previously Healthy Children and  
348 Adolescents in New York City. *JAMA - J Am Med Assoc*. 2020;324(3):294–6.
- 349 3. Whittaker E, Bamford A, Kenny J, Kaforou M, Jones CE, Shah P, et al. Clinical  
350 Characteristics of 58 Children with a Pediatric Inflammatory Multisystem Syndrome  
351 Temporally Associated with SARS-CoV-2. *JAMA - J Am Med Assoc*. 2020;324(3):259–69.
- 352 4. Licciardi F, Pruccoli G, Denina M, Parodi E, Taglietto M. SARS-CoV-2 – Induced Kawasaki-  
353 Like Hyperinflammatory Syndrome □: A Novel COVID Phenotype in Children. *Pediatrics*.  
354 2021;146(2):1–5.
- 355 5. Dufort EM, Koumans EH, Chow EJ, Rosenthal EM, Muse A, Rowlands J, et al. Multisystem  
356 Inflammatory Syndrome in Children in New York State. *N Engl J Med*. 2020;383(4):347–58.
- 357 6. Assessment RR. European Centre for Disease Prevention and Control Country Experts. Rapid  
358 Risk Assessment: Paediatric inflammatory multisystem syndrome and SARS-CoV-2 infection  
359 in children. [https://www.ecdc.europa.eu/sites/default/files/documents/covid-19-risk-](https://www.ecdc.europa.eu/sites/default/files/documents/covid-19-risk-assessment)  
360 [assessment](https://www.ecdc.europa.eu/sites/default/files/documents/covid-19-risk-assessment). 2020;(May):1–18.
- 361 7. HAN Archive - 00432 | Health Alert Network (HAN) [Internet]. [cited 2021 Dec 14].  
362 Available from: <https://emergency.cdc.gov/han/2020/han00432.asp>
- 363 8. Royal College of Paediatrics and Child Health. Guidance paediatric multisystem inflammatory  
364 syndrome temporally associated with Cov-19. *R Coll Paediatr Child Heal*. 2020;1–6.
- 365 9. Jiang L, Tang K, Levin M, Irfan O, Morris SK, Wilson K, et al. COVID-19 and multisystem  
366 inflammatory syndrome in children and adolescents. *Lancet Infect Dis*. 2020;20(11):e276–88.
- 367 10. Feldstein LR, Tenforde MW, Friedman KG, Newhams M, Rose EB, Dapul H, et al.  
368 Characteristics and Outcomes of US Children and Adolescents with Multisystem

- 369 Inflammatory Syndrome in Children (MIS-C) Compared with Severe Acute COVID-19.  
370 JAMA - J Am Med Assoc. 2021;325(11):1074–87.
- 371 11. Son MBF, Murray N, Friedman K, Young CC, Newhams MM, Feldstein LR, et al.  
372 Multisystem Inflammatory Syndrome in Children — Initial Therapy and Outcomes. N Engl J  
373 Med. 2021;385(1):23–34.
- 374 12. Davies P, Evans C, Kanthimathinathan HK, Lillie J, Brierley J, Waters G, et al. Intensive care  
375 admissions of children with paediatric inflammatory multisystem syndrome temporally  
376 associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study. Lancet  
377 Child Adolesc Heal. 2020;4(9):669–77.
- 378 13. Payne AB, Gilani Z, Godfred-Cato S, Belay ED, Feldstein LR, Patel MM, et al. Incidence of  
379 Multisystem Inflammatory Syndrome in Children Among US Persons Infected With SARS-  
380 CoV-2. JAMA Netw Open [Internet]. 2021 Jun 1 [cited 2021 Dec 14];4(6):e2116420–  
381 e2116420. Available from:  
382 <https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2780861>
- 383 14. Flood J, Shingleton J, Bennett E, Walker B, Amin-Chowdhury Z, Oligbu G, et al. Paediatric  
384 multisystem inflammatory syndrome temporally associated with SARS-CoV-2 (PIMS-TS):  
385 Prospective, national surveillance, United Kingdom and Ireland, 2020. Lancet Reg Heal - Eur  
386 [Internet]. 2021 Apr 1 [cited 2021 Dec 14];3. Available from:  
387 <http://www.thelancet.com/article/S2666776221000521/fulltext>
- 388 15. Godfred-Cato S, Bryant B, Leung J, Oster ME, Conklin L, Abrams J, et al. COVID-19-  
389 Associated Multisystem Inflammatory Syndrome in Children - United States, March-July  
390 2020. MMWR Morb Mortal Wkly Rep [Internet]. 2020 Aug 14 [cited 2021 Dec  
391 14];69(32):1074–80. Available from: <https://pubmed.ncbi.nlm.nih.gov/32790663/>
- 392 16. Geva A, Patel MM, Newhams MM, Young CC, Son MBF, Kong M, et al. Data-driven  
393 clustering identifies features distinguishing multisystem inflammatory syndrome from acute  
394 COVID-19 in children and adolescents. EClinicalMedicine [Internet]. 2021;40:09–10.  
395 Available from: <https://doi.org/10.1016/j.eclinm.2021.101112>
- 396 17. Linzer DA, Lewis JB. polCA: An R package for polytomous variable latent class analysis. J  
397 Stat Softw. 2011;42(10):1–29.
- 398 18. COVID-19 [Internet]. [cited 2022 Feb 27]. Available from:  
399 <https://covid19.healthdata.org/mexico/mexico-city?view=vaccinations&tab=trend>
- 400 19. COVID-19 Data Explorer - Our World in Data [Internet]. [cited 2022 Feb 26]. Available from:  
401 <https://ourworldindata.org/explorers/coronavirus-data-explorer>
- 402 20. Ramaswamy A, Brodsky NN, Sumida TS, Comi M, Asashima H, Hoehn KB, et al. Immune  
403 dysregulation and autoreactivity correlate with disease severity in SARS-CoV-2-associated  
404 multisystem inflammatory syndrome in children. Immunity. 2021;54(5):1083-1095.e7.
- 405 21. Belay ED, Abrams J, Oster ME, Giovanni J, Pierce T, Meng L, et al. Trends in Geographic  
406 and Temporal Distribution of US Children with Multisystem Inflammatory Syndrome during  
407 the COVID-19 Pandemic. JAMA Pediatr. 2021;175(8):837–45.

- 408 22. States U, July M, Godfred-cato S, Bryant B, Leung J, Oster ME, et al. COVID-19–Related  
409 Multisystem Inflammatory Syndrome in Children. *AAP Gd Rounds*. 2020;44(3):30–30.
- 410 23. Torres JP, Izquierdo G, Acuña M, Pavez D, Reyes F. Multisystem inflammatory syndrome in  
411 children (MIS-C): Report of the clinical and epidemiological characteristics of cases in  
412 Santiago de Chile during the SARS-CoV-2 pandemic Juan. *Int J Infect Dis*.  
413 2020;2020(100):75–81.
- 414 24. Antúnez-Montes OY, Escamilla MI, Figueroa-Uribe AF, Arteaga-Menchaca E, Lavariega-  
415 Saráchaga M, Salcedo-Lozada P, et al. COVID-19 and Multisystem Inflammatory Syndrome  
416 in Latin American Children: A Multinational Study. *Pediatr Infect Dis J*. 2020;40(1):1–6.
- 417 25. Flood J, Shingleton J, Bennett E, Walker B, Amin-Chowdhury Z, Oligbu G, et al. Paediatric  
418 multisystem inflammatory syndrome temporally associated with SARS-CoV-2 (PIMS-TS):  
419 Prospective, national surveillance, United Kingdom and Ireland, 2020. *Lancet Reg Heal - Eur*  
420 [Internet]. 2021 Apr 1 [cited 2021 Dec 14];3:100075. Available from:  
421 <http://www.thelancet.com/article/S2666776221000521/fulltext>
- 422 26. Mohsin SS, Abbas Q, Chowdhary D, Khalid F, Sheikh AS, Khan ZGA, et al. Multisystem  
423 inflammatory syndrome (MIS-C) in Pakistani children: A description of the phenotypes and  
424 comparison with historical cohorts of children with Kawasaki disease and myocarditis. *PLoS*  
425 *One*. 2021;16(6 June):1–13.
- 426 27. Vella LA, Rowley AH. Current Insights Into the Pathophysiology of Multisystem  
427 Inflammatory Syndrome in Children. *Curr Pediatr Rep* [Internet]. 2021;9(4):83–92. Available  
428 from: <https://doi.org/10.1007/s40124-021-00257-6>
- 429 28. Gruber C, Patel R, Trachman R, Lepow L, Amanat F, Krammer F, et al. Mapping systemic  
430 inflammation and antibody responses in multisystem inflammatory syndrome in children  
431 (MIS-C). *medRxiv Prepr Serv Heal Sci*. 2020;(January).
- 432 29. Sacco K, Castagnoli R, Vakkilainen S, Liu C, Delmonte OM, Oguz C, et al.  
433 Immunopathological signatures in multisystem inflammatory syndrome in children and  
434 pediatric COVID-19. *Nat Med*. 2022;
- 435 30. Consiglio CR, Cotugno N, Sardh F, Pou C, Amodio D, Rodriguez L, et al. The immunology of  
436 multisystem inflammatory syndrome in children with COVID-19. *medRxiv*. 2020;(January).
- 437 31. Harwood R, Allin B, Jones CE, Whittaker E, Ramnarayan P, Ramanan A V., et al. A national  
438 consensus management pathway for paediatric inflammatory multisystem syndrome  
439 temporally associated with COVID-19 (PIMS-TS): results of a national Delphi process. *Lancet*  
440 *Child Adolesc Heal*. 2021;5(2):133–41.
- 441 32. Eiros R, Barreiro-Pérez M, Martín-García A, Almeida J, Villacorta E, Pérez-Pons A, et al.  
442 Pericardial and myocardial involvement after SARS-CoV-2 infection: a cross-sectional  
443 descriptive study in healthcare workers. *Rev Española Cardiol (English Ed)*. 2021;
- 444 33. McArdle AJ, Vito O, Patel H, Seaby EG, Shah P, Wilson C, et al. Treatment of Multisystem  
445 Inflammatory Syndrome in Children. *N Engl J Med*. 2021;385(1):11–22.

| <b>Chart 1. Case definition criteria for PIMS</b>             |  |
|---|--|
| 1. Fever  |  |
| 2. Elevation of inflammation markers                          | At least one of the following: <ul style="list-style-type: none"> <li>• C-Reactive Protein (CRP) &gt;5mg/L</li> <li>• Procalcitonin &gt; 0.15 ng/ml</li> <li>• Ferritin &gt; 300 mcg/L</li> <li>• Fibrinogen &gt; 400 mg/dl</li> <li>• D-Dimer &gt;560 ng/ml</li> <li>• Neutrophils &gt; 7500 cells/mcl</li> <li>• Lymphopenia: &lt;2 years: &lt;4000, 2-3 years: &lt; 3000, &gt;4 years: &lt;1500 cells/mcl</li> <li>• Albumin &lt; 3 g/dl</li> </ul> |
| 3. At least two systems involved                              | 3.1 Cardiovascular. At least one of the following: <ul style="list-style-type: none"> <li>• Required vasoactive drug</li> <li>• Left ventricular ejection fraction &lt; 55%</li> </ul>   |
|   | 3.2 Respiratory. At least one of the following:<br>3.3 Supplementary oxygen with non-rebreathable mask or higher oxygen concentration device. <ul style="list-style-type: none"> <li>• Oxygen saturation &lt;90%</li> <li>• Pulmonary infiltrates in chest X-Ray or Computed Tomography</li> </ul>   |
|   | 3.4 Neurologic. At least one of the following:<br>3.5 Glasgow score < 14 if not sedated <ul style="list-style-type: none"> <li>• Meningismus</li> <li>• Seizures</li> </ul>  |
|   | 3.4 Hematologic. At least one of the following: <ul style="list-style-type: none"> <li>• Plateletes &lt; 150 000 cells/mcl</li> <li>• Prothrombin time &gt;14 sec</li> </ul>   |
|   | 3.5 Gastrointestinal. At least one of the following: <ul style="list-style-type: none"> <li>• Abdominal pain</li> <li>• Vomit</li> <li>• Diarrhea</li> <li>• Alanine aminotransferase (ALT) &gt; 90 U/L</li> </ul>   |
|   | 3.6 Mucocutaneous. At least one of the following: <ul style="list-style-type: none"> <li>• Rash</li> <li>• Extremity edema</li> <li>• Desquamation</li> <li>• Mucosal inflammation</li> <li>• Conjunctivitis</li> </ul>  |
|   | 3.7. Renal<br>Creatinine > twice upper limit of the reference range for age  |
| 4. Hospitalization  |  |
| 5. No alternative diagnosis                                   | <ul style="list-style-type: none"> <li>• No positive blood culture during the first 48 hours in the hospital</li> <li>• In uncertain cases, complete file review and consensus by an expert panel.</li> </ul>  |
| 6. Present or recent infection by SARS-COV2                   | At least one of the following <ul style="list-style-type: none"> <li>• Positive RT-PCR<sup>1</sup> for SARS-CoV-2</li> <li>• Positive serology for SARS-CoV-2</li> <li>• Contact with a confirmed positive COVID-19 case in the last four weeks.</li> </ul>  |
| <sup>1</sup> Reverse transcriptase polymerase chain reaction. |  |

**Table.1 Clinical presentation of cases with PIMS**

|  | Total population<br>(N=75) <sup>1</sup> | Without serious<br>underlying<br>disease <sup>2</sup><br>(N=60) <sup>1</sup> | Cluster 1<br>With GIS <sup>3</sup> or<br>Rash<br>(N=60) <sup>1</sup> | Cluster 2<br>Predominant respiratory<br>(N=15) <sup>1</sup> | p *              |
|--|---|--|--|---|------------------|
| Female sex -no. (%)  | 39 (52%)                                | 33(55%)  | 33 (55%)   | 6 (40%)   | 0.23             |
| Age - median (IQR)   | 10.9 (5.6-15.6)                         | 10.6 (5.5-15.0)  | 10.3 (5.7-13.5)  | 15.3 (5.4-16.6)   | 0.08             |
| Age group - n (%)  |   |  |  |   |                  |
| 4<1 y  | 5 (6.7%)                                | 5 (8.3%)   | 4(6.7%)  | 1 (6.7%)  |                  |
| 1-4 y  | 11 (17.3%)                              | 9 (15%)  | 9 (15%)  | 2 (1.3%)  |                  |
| 5-9 y  | 13 (17.1%)                              | 11 (18.3%)   | 12 (0.2%)  | 1 (6.7%)  | 0.12             |
| 10-14 y  | 26 (34.7%)                              | 21 (35%)   | 23 (38.3%)   | 3 (20%)   |                  |
| 15-18 y  | 20 (26.7%)                              | 14 (23.3%)   | 12 (20%)   | 8 (53%)   |                  |
| Days of symptoms before admission  | 7(4-9)                                  | 7 (5-9)  | 6 (4-8)  | 7 (1-9)   |                  |
| <b>Symptom's onset posterior to June 1, 2021</b>                         | <b>11 (14.7%)</b>                       | <b>10 (16.7%)</b>  | <b>10 (16.7%)</b>  | <b>1 (6.7%)</b>   | 0.30             |
| <b>SARS-COV2 testing, No. (%)</b>  |   |  |  |   |                  |
| RT- PCR positive   | 57/ 71 (80%)                            | 43/ 56 (76.8%)   | 44/58 (75.9%)  | 13/13 (100%)  | <b>0.04</b>      |
| Serology positive  | 25/ 41 (61%)                            | 25/46 (54%)  | 25/ 36(69%)  | 0/5*  | <b>0.01</b>      |
| <b>Underlying medical conditions - no. (%)</b>                           |   |  |  |   |                  |
| Obesity (BMI > 95 <sup>o</sup> percentile)                               | 18 (24%)                                | 14 (23.0%)   | 12 (20%)   | 6 (40%)   | 0.10             |
| Respiratory  | 5 (6.7%)                                | 3 (5%)   | 2 (3.3%)   | 3(20%)  | 0.05             |
| Neuromuscular  | 6 (8.0%)                                | 0  | 2 (3.3%)   | 4 (26.7%)   | <b>0.01</b>      |
| Cardiovascular   | 3 (4%)                                  | 0  | 2 (3.3%)   | 1 (6.7%)  | 0.49             |
| Cancer   | 7 (9.3%)                                | 0  | 2 (3.3%)   | 5 (33%)   | <b>0.003</b>     |
| Other, immunosuppression   | 2 (3%)                                  | 0  | 1 (1.7%)   | 1 (6.7%)  | 0.32             |
| Other comorbidity  | 10 (13.3%)                              | 6 (10%) <sup>4</sup>   | 8 (13.3%)  | 2 (13.3%)   | 0.64             |
| At least 1 underlying condition  | 34 (45.3%)                              | 19 (31.2%)   | 22 (36.7%)   | 12 (80%)  | <b>0.003</b>     |
| <b>Clinical manifestations – no. (%)</b>                                 |   |  |  |   |                  |
| Cough  | 39(52%)                                 | 32 (53.3%)   | 33 (55%)   | 6 (40%)   | 0.23             |
| Rash   | 36 (48%)                                | 33 (55%)   | 36 (60%)   | 0   | <b>&lt;0.001</b> |
| Conjunctivitis   | 39 (50.6 %)                             | 39 (52%)   | 36 (60%)   | 2 (13.3%)   | <b>0.001</b>     |
| Diarrhea   | 33 (44%)                                | 27 (45%)   | 33 (55%)   | 0   | <b>&lt;0.001</b> |
| Emesis   | <b>36 (48%)</b>                         | <b>33 (55%)</b>  | <b>36(60%)</b>   | <b>0</b>  | <b>&lt;0.001</b> |
| Abdominal pain   | 38 (51%)                                | 36 (60%)   | 38 (63.3%)   | 0   | <b>&lt;0.001</b> |
| Headache   | 34(45.3%)                               | 25 (41.7%)   | 27 (45%)   | 7 (46.7%)   | 0.57             |
| Rhinorrhea   | 24 (32%)                                | 20 (33.3%)   | 19 (31.7%)   | 5 (33.2%)   | 0.56             |
| Respiratory Distress   | 31 (41%)                                | 24 (40%)   | 21 (35%)   | 10 (66.7%)  | <b>0.03</b>      |
| Lower respiratory symptoms   | 41 (54%)                                | 31 (51.7%)   | 29 (48.3%)   | 12 (80%)  | <b>0.03</b>      |
| Anosmia/Dysgeusia  | 7 (9.3%)                                | 6 (10%)  | 4 (6.6%)   | 3 (20%)   | 0.14             |
| Arthralgias/Myalgias   | 14(18.7%)                               | 11 (18.3%)   | 13 (21.7%)   | 1 (6.7%)  | 0.17             |
| Oxygen Saturation<90%  | 30 (40%)                                | 20 (33.3%)   | 22 (36.7%)   | 8 (53.3%)   | 0.19             |
| <b>Laboratory values within 72 h of admission – median (IQR) / n (%)</b> |   |  |  |   |                  |
| Neutrophil count x10 <sup>6</sup> cells/mcl                              | 6.1 (1.7-9.2)                           | 7.1(3.1-10.1)  | 6-5 (1.9-9.8)  | 3.1(0.5-7.1)  | <b>0.04</b>      |
| Neutrophilia (>7500 cells/mm <sup>3</sup> )                              | 29/74 (39.2 %)                          | 27/59 (45.8%)  | 27/59 (45.8%)  | 2 (13.3%)   | <b>0.02</b>      |
| Neutropenia (<1000 caks/mm <sup>3</sup> )                                | 10 (13%)                                | 6 (10%)  | 5/59 (8.5%)  | 5 (33%)   | <b>0.02</b>      |
| Lymphocyte count x10 <sup>6</sup> cells/mm <sup>3</sup>                  | 1.5 (0.5-2.4)                           | 1.6 (0.8-2.1)  | 1.6 (0.6-2.8)  | 0.8 (0.4-1.8)   | <b>0.16</b>      |
| Lymphopenia <sup>5</sup>   | 43/73 (58.9 %)                          | 33/58 (56.9%)  | 33/58 (56.9%)  | 10 (66.7%)  | 0.35             |
| Platelets x 10 <sup>3</sup> cells/mm <sup>3</sup>                        | 162 (94-250)                            | 166(110-271)   | 162 (105-235)  | 162 (43-330)  | 0.82             |
| Fibrinogen, mg/dl  | 510 (404-668)                           | 558(431-724)   | 516 (412-671)  | 510 (361-669)   | 0.66             |
| Fibrinogen> 400 mg/dl  | 52 (69.3%)                              | 44/56 (78.6%)  | 43 (71.7%)   | 10 (76.9%)  | 0.5              |
| Ferritin, mcg/L  | 617 (407-1370)                          | 559 (380-1110)   | 604 (417-1150)   | 1370 (325-6071)   | 0.25             |
| Ferritin> 300 mg/dl  | 53 (70.1%)                              | 41 (68.3%)   | 46/55 (83.6%)  | 7/9 (77.7%)   | 0.49             |
| D-Dimer ng/L   | 2.6 (1.1-6.5)                           | 2.9(1.2-8.8)   | 3.5(1.3-9.5)   | 0.8 (0.5-1.2)   | <b>&lt;0.001</b> |
| D- Dimer> 560ng/ml (0.56 ng/L)   | 66/74 (89.2%)                           | 55 (91.7%)   | 55/59 (93%)  | 11/15 (73.3%)   | <b>0.05</b>      |
| C-reactive protein (mg/L)  | 9.8 (4.5-18.9)                          | 13.5 (6.1-19.9)  | 13.2 (5.9-19.1)  | 7.3 (0.7-17.7)  | 0.36             |
| C-reactive protein > 5mg/L   | 47/63 (74.6%)                           | 41/50 (82%)  | 42/54 (77.8%)  | 5/9 (55.5%)   | 0.16             |
| Procalcitonin ng/ml  | 1.85 (0.5-6.3)                          | 1.8(0.47-3.84)   | 2.1 (1.16-6.4)   | 0.37 (0.12-6.17)  | 0.12             |
| Procalcitonin > 0.15ng/ml  | 55/62 (88.7%)                           | 43/50 (86%)  | 47/51 (92%)  | 8/11 (72.7%)  | 0.1              |
| Albumin< 3g/dl   | 45/71 (63.3%)                           | 36/56 (64.3%)  | 40/57 (70.2%)  | 5/14 (35.7%)  | <b>0.02</b>      |

<sup>1</sup>N in the column heading was used to calculate proportions if not otherwise specified. For variables with missing data, denominators are reported in each cell.<sup>2</sup>Excluded: cancer, immunodeficiency, neuromuscular, chronic respiratory disease except asthma, congenital cardiopathies, chronic kidney failure.<sup>3</sup>GIS: Gastrointestinal symptoms, includes abdominal pain, diarrhea, emesis.<sup>4</sup>Trisomy 21 (n=1), Post recent appendectomy (n=2), hypothyroidism (n=2), undernutrition (n=1).<sup>5</sup>Lymphopenia: (<2 years: <4000, 2-3 years: < 3000, >4 years: <1500 cells/mcl)  
\*O one-sided Fisher exact test/ Mann-Whitney test for comparison between cluster 1 and cluster 2.



|  | <b>Total sample(N=75)<sup>1</sup></b> | <b>Without serious underlying disease (N=60)<sup>1</sup></b> | <b>Cluster 1 With GIS or rash (N=60)<sup>1</sup></b> | <b>Cluster 2 Predominant respiratory (N=15)<sup>1</sup></b> | <b>p*</b>        |
|--|---------------------------------------|--|--|---|------------------|
| <b>Treatment – no. (%)</b>                         |                                       |  |  |   |                  |
| Intravenous immune globulin                        | 34(45.3%)                             | 32(53.3%)  | 33 (55%)   | 1 (6.7%)  | <b>0.01</b>      |
| Systemic steroids                                  | 48 (64.0%)                            | 43 (71.7%)   | 44 (73.3%)   | 4 (26.7%)   | <b>0.001</b>     |
| Anticoagulation therapy                            | 47 (62.7%)                            | 40 (66.7%)   | 41 (68%)   | 6 (40%)   | <b>0.04</b>      |
| <b>Maximum ventilatory support needed - no (%)</b> |                                       |  |  |   |                  |
| Non-rebreather mask                                | 8 (10.7%)                             | 7 (11.7%)  | 1 (1.7%)   | 1 (6.7%)  |                  |
| High flow nasal cannula                            | 4 (5.3%)                              | 2 (3.3%)   | 2 (3.3%)   | 2 (13.3%)   |                  |
| Non-invasive mechanical ventilation                | 4 (5.3%)                              | 4 (6.7%)   | 4 (6.7%)   | 0   |                  |
| Invasive mechanical ventilation                    | 33 (44 %)                             | 25 (41.7%)   | 25 (41.7%)   | 9 (60%)   | 0.16             |
| Any infiltrates in chest Rx or CT                  | 60/71 (85%)                           | 48/56 (85.7%)  | 45/56 (80%)  | 15 (100%)   | 0.06             |
| Severe respiratory involvement <sup>2</sup>        | 28 (37.3%)                            | 21 (35%)   | 19 (31.7%)   | 9 (60%)   | <b>0.04</b>      |
| <b>Cardiovascular involvement – no (%)</b>         |                                       |  |  |   |                  |
| LVEF <sup>3</sup> <55%                             | 30 (40.0%)                            | 24 (40%)   | 22 (36.7%)   | 8 (53.3%)   | 0.18             |
| LVEF<45%   | 6 (8.0%)                              | 5 (8.3%)   | 6 (10%)  | 0   | 0.25             |
| LVEF <35%  | 0                                     | 0  | 0  | 0   |                  |
| Coronary aneurysm (z score > 2.5)                  | 5 (6.7%)                              | 5(8.3%)  | 5 (8.3%)   | 0   | 0.32             |
| Coronary dilatation (z score >2 - <2.5)            | 0                                     | 0  | 0  | 0   |                  |
| Vasopressor support – no (%)                       | 39 (52.0%)                            | 30 (50%)   | 32 (53.3%)   | 7 (46.7%)   | 0.43             |
| <b>Hematologic involvement</b>                     |                                       |  |  |   |                  |
| Thromboplastin time > 14 s                         | 37/72 (51.5%)                         | 30 (50%)   | 39 (65%)   | 12 (80%)  | 0.26             |
| Platelets count <150 000 cell/mcl                  | 29 (38.7%)                            | 21 (35%)   | 24 (40%)   | 6 (40%)   | 1.0              |
| <b>Neurologic involvement <sup>4</sup></b>         |                                       |  |  |   |                  |
| Gastrointestinal involvement                       | 5 (6.7%)                              | 5 (8.3%)   | 5 (8.3%)   | 0   | 0.32             |
| Alanine Aminotransferase (ALT) > 90 U/L            | 60 (80%)                              | 51 (85%)   | 57 (95%)   | 3 (20%)   | <b>&lt;0.001</b> |
| Mucocutaneous involvement                          | 21/72 (29.2%)                         | 16/58 (27.6%)  | 17/58 (29.3%)  | 4/14 (28.5%)  | 0.62             |
| Acute Kidney Injury, stage 2 <sup>5</sup>          | 64 (85.3%)                            | 39 (65%)   | 58 (96.7%)   | 6 (40%)   | <b>&lt;0.001</b> |
|  | 19/74 (25.7%)                         | 26.7%  | 19 (31.7%)   | 0   | <b>0.01</b>      |
| <b>Clinical outcomes- no. (%) / median (IQR)</b>   |                                       |  |  |   |                  |
| ICU <sup>6</sup> admission                         | 48 (64%)                              | 37 (61%)   | 38 (63%)   | 10 (66.7%)  | 0.53             |
| Length of ICU stay-d (n=48)                        | 5 (3-8)                               | 4(3-8)   | 4.5 (3-8.3)  | 7.5 (3.5-13.5)  | 0.23             |
| Length of Hospital stay days                       | 7 (4-13)                              | 7(4-11)  | 7 (4-12)   | 10 (5-17)   | 0.31             |
| Died   | 2 (2.7%)                              | 0  | 1 (1.7%)   | 1 (6.7%)  | 0.36             |

<sup>1</sup> N in the column heading was used to calculate proportions if not otherwise specified. For variables with missing data, denominators are reported in each cell. <sup>2</sup>Rx: chest X-ray, CT: Computed tomography. Severe respiratory involvement was defined as oxygen requirement and infiltrates in thoracic imaging. <sup>3</sup>LVEF= Left ventricular ejection fraction. <sup>4</sup>Neurologic involvement: seizures (n=3), optic neuritis (n=1), meningismus (n=1), headache not included. <sup>5</sup>Acute Kidney Injury (AKI) was defined as an increase greater than two times the upper limit of the reference range for gender and age. <sup>6</sup> ICU: intensive care unit.

\* Comparison Cluster 1 vs. cluster 2with Fisher exact test/ Mann-Whitney test

448

449

450


451

452

453

454 **Figure 1.** Temporal distribution of PIMS cases by cluster from May 1<sup>st</sup>, 2020 (Week 19, 2020) to  
455 September 30, 2021 (Week 40, 2021).

456



457

